arrow
M

Manuela Rabaglio

department of medical oncology
H指数:34
被引数:7,490

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)

TLD-1,一种新型脂质体多柔比星,在实体瘤患者中的比较药代动力学及一项多中心Ⅰ期研究(SAKK 65/16)的最终结果

2025-11-180
PRE
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer

SAKK 21/12临床试验二期:CR1447经皮给药治疗转移性乳腺癌的最终总生存期分析

2025-05-240
PRE
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer

影响年轻乳腺癌患者5年坚持辅助内分泌治疗的因素

BREAST
IF7.9
2024-10-010
OAAI
Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial
2024-05-020
PRE
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
2024-04-013
OAAI
Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer
2023-03-010
PRE
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland
2022-06-103
PRE
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer The MA.32 Randomized Clinical Trial
2022-05-24108
OA
CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)
2022-02-152
PRE
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
2021-10-0119
OA
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
2021-07-2810
OAAI